Prs44 - Informing the Pathway of Copd Treatment (Impact Study) - Single Inhaler Triple Therapy (Ff/Umec/Vi) Versus Umec/Vi in Patients With Copd: Cost-Effectiveness Analysis From a Societal Perspective in Quebec

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2438
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prs46 - Informing the Pathway of Copd Treatment (Impact Study) - Single Inhaler Triple Therapy (Ff/Umec/Vi) Versus Ff/Vi in Patients With Copd: Cost-Effectiveness Analysis From a Societal Perspective in Quebec

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Prs24 - Informing the Pathway of Copd Treatment (Impact Study) - Single Inhaler Triple Therapy (Ff/Umec/Vi) Versus Ff/Vi and Umec/Vi in Patients With Copd: Healthcare Resource Utilization Data and Associated Costs – Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI and UMEC/VI in Patients With COPD: Efficacy and Safety in a Japanese Population

International Journal of COPD
EnvironmentalPublic HealthHealth PolicyMedicinePulmonaryRespiratory MedicineOccupational Health
2019English

Prs39 - Cost-Effectiveness of a New Single Inhaler Triple Therapy (Sitt) Versus Multiple Inhaler Triple Therapies (Mitt) to Treat Chronic Obstructive Pulmonary Disease (Copd) in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of Glycopyrronium Compared to Tiotropium in COPD Patients From a Swedish Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Prs21 - Economic Impact of Delaying Initiation With Multiple Inhaler Maintenance Triple Therapy Treatment in Spanish Copd Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P272 Improvements in Exacerbation Rates With Single Inhaler Triple Therapy Versus Dual Ics/Laba Therapy in Patients With Advanced Chronic Obstructive Pulmonary Disease (Copd): Subgroup Analyses of the Phase Iii Fulfil Study

2017English

P272 Improvements in Exacerbation Rates With Single Inhaler Triple Therapy Versus Dual Ics/Laba Therapy in Patients With Advanced Chronic Obstructive Pulmonary Disease (Copd): Subgroup Analyses of the Phase Iii Fulfil Study

2017English

Prs57 - Economic Evaluation of Single Inhaler Triple Therapy for Patients With Chronic Obstructive Pulmonary Disease (Copd) Using the Galaxy Model

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy